CIPLA


Also found in: Wikipedia.
AcronymDefinition
CIPLAChemical, Industrial & Pharmaceutical Laboratories
CIPLACleveland Intellectual Property Law Association (Cleveland, OH)
CIPLAColumbus Intellectual Property Law Association (Columbus, OH)
CIPLAConnecticut Intellectual Property Law Association
References in periodicals archive ?
The aggrieved couple also laid criminal complaints accusing Cipla of trading without a valid drug registration certificate and failing to include appropriate and timely health packaging warnings.
Jerome Smith, CEO of Enaleni Pharmaceuticals Ltd and founder of Cipla Medpro, says the launch of a single-tablet once-daily lamivudine is a significant development for patient groups where adherence to medication and pill burden is problematic.
For AIDS drugs, a three-drug cocktail that brand-name companies sold for $10,000 a year or more per person a few years ago is now available from Cipla and other generic firms for as little as $140 a year.
The bottle of Neverapine costs Cipla less than forty cents to produce, Haddad says, and each one contains about 200 doses.
Based on an assessment of Velcera and Cipla's chances of succeeding on their appeal and weighing the equities, the Court of Appeals held that Cipla and Velcera had not established that a further stay was warranted.
We are pleased to have been granted the benefits of orphan drug designation in Europe," said Mr Chandru Chawla, Head of Cipla New Ventures .
As per Cipla , deal is effective January 1, 2015 and will run for a period of three years and from the 4Q the financial year 2015, the supplies will commence.
Cipla Medpro South Africa, the South African subsidiary of the Indian firm Cipla, also recorded a 28% increase in revenue in the six months ended 30 June 2012 to R1,080b11 ($123m).
This initiative of price reduction is a humanitarian approach by Cipla to support cancer patients," company chairman Y.
Love points to one positive development: the agreement whereby Cipla Ltd.
On February 6, the Indian generic manufacturer CIPLA offered to sell a triple combination HIV treatment (d4T, 3TC, and nevirapine) for less than a dollar a day to MSF (Doctors Without Borders); it offered a price of $600 per year to governments.
A ranking of the major companies in this industry are included in the final part of this report, where current leading players include Ranbaxy, Dr Reddys, Cipla and Lupin.